xenotransplant
possibl
solut
shortag
tissu
human
transplant
multipl
hurdl
exist
clinic
xenotransplant
includ
immunolog
barrier
metabol
differ
pig
sourc
speci
commonli
consid
human
ethic
concern
sinc
clinic
trial
first
propos
almost
year
ago
degre
risk
infect
transmit
xenograft
donor
recipi
extens
investig
number
potenti
viral
pathogen
identifi
includ
porcin
endogen
retroviru
perv
porcin
cytomegaloviru
pcmv
porcin
lymphotrop
herpesviru
plhv
sensit
diagnost
assay
develop
viru
humantrop
perv
exogen
recombin
perva
pervc
sequenc
present
subset
swine
porcin
cytomegaloviru
exclud
herd
sourc
anim
earli
wean
piglet
contrast
risk
associ
plhv
remain
undefin
microbiolog
studi
assay
potenti
xenogen
pathogen
further
understand
risk
associ
xenotransplant
thu
far
clinic
xenotransplant
pig
tissu
result
transmiss
viral
infect
human
signific
risk
diseas
transmiss
swine
human
confirm
immunolog
hurdl
overcom
reason
initi
care
monitor
clinic
trial
mani
peopl
await
organ
cell
transplant
worldwid
other
might
benefit
organ
transplant
either
yet
sick
enough
place
offici
wait
list
suffer
diseas
diabet
cirrhosi
might
treat
organ
islet
cellular
transplant
suppli
tissu
increas
dramat
alexi
carrel
suggest
futur
transplant
treatment
organ
failur
heterotransplant
transplant
cell
tissu
vascular
organ
nonhuman
speci
human
term
xenotransplant
would
theoret
advantag
provid
unlimit
suppli
transplant
organ
either
perman
organ
replac
bridg
avail
humanderiv
organ
addit
organ
might
resist
infect
common
human
pathogen
hepat
c
viru
hiv
unfortun
multipl
barrier
current
exist
broad
applic
xenotransplant
includ
immunolog
mediat
graft
reject
xenogen
tissu
possibl
metabol
molecular
incompat
donor
organ
human
ethic
concern
risk
infect
might
transmit
donor
speci
human
recipi
gener
human
popul
likelihood
clinic
success
xenotransplant
initi
enhanc
develop
genet
modifi
swine
express
human
complement
regulatori
protein
recent
pig
produc
disrupt
gene
enzym
swine
unabl
express
gal
sugar
cell
major
endotheli
antigen
target
hyperacut
humor
graft
reject
combin
immun
suppress
use
organ
across
histocompat
barrier
absenc
preexist
immun
recipi
animalderiv
organ
render
host
suscept
infect
consequ
infect
like
remain
signific
barrier
xenotransplant
even
immun
barrier
breach
inde
public
attent
regard
xenotransplant
focus
less
immunolog
hurdl
possibl
spread
infect
nonhuman
speci
human
xenograft
recipi
commun
larg
theoret
risk
merit
reconsider
light
data
assembl
past
year
regard
degre
infecti
risk
pose
xenotransplant
experi
immunocompromis
patient
suggest
novel
pathogen
may
emerg
caus
infect
includ
organ
normal
associ
human
diseas
transplant
pose
uniqu
epidemiolog
hazard
due
effici
transmiss
pathogen
particularli
virus
graft
term
xenosi
also
direct
zoonosi
xenozoonosi
coin
reflect
uniqu
epidemiolog
infect
result
organ
carri
xenogen
tissu
number
factor
may
increas
risk
infect
xenotransplant
r
xenograft
serv
permiss
reservoir
donor
organ
bypass
host
defens
without
need
vector
achiev
diseas
transmiss
r
lack
knowledg
behavior
organ
donor
speci
immunosuppress
human
r
inabl
recogn
novel
clinic
syndrom
result
infect
pathogen
r
lack
clinic
laboratori
assay
organ
nonhuman
speci
r
donorderiv
organ
may
caus
diseas
nativ
host
speci
may
caus
diseas
new
host
xenotrop
organ
may
acquir
new
characterist
genet
recombin
mutat
r
donorrecipi
incompat
major
histocompat
mhc
antigen
may
reduc
efficaci
host
immun
respons
infect
within
xenograft
swine
often
consid
sourc
speci
xenograft
nonhuman
primat
closer
immunolog
human
ethic
issu
risk
transmiss
virus
known
infecti
human
poor
size
match
expens
difficulti
breed
exclud
option
concern
rais
regard
infecti
risk
associ
use
nonhuman
primat
organ
donor
human
led
us
food
drug
administr
preclud
use
speci
organ
donor
human
swine
immunolog
dissimilar
easier
breed
good
size
match
human
genet
engin
express
suppress
specif
gene
relev
transplant
initi
microbiolog
concern
focus
pigderiv
bacteria
parasit
organ
streptococcu
sui
could
easili
character
clinic
microbiolog
laboratori
howev
abil
exclud
extracellular
organ
bacteria
herd
swine
destin
use
organ
donor
focus
attent
potenti
viral
pathogen
theoret
concern
regard
transmiss
novel
pathogen
pig
human
gain
substanc
descript
famili
porcin
endogen
retrovirus
perv
demonstr
famili
virus
capabl
infect
human
cell
vitro
character
potenti
pathogen
swine
provid
evidencebas
approach
infect
prevent
xenotransplant
main
hurdl
success
xenotransplant
immunolog
hyperacut
graft
reject
har
effect
preform
natur
antibodi
present
human
old
world
primat
ubiquit
gal
epitop
express
porcin
vascular
endotheli
cell
har
bind
antibodi
complement
deposit
result
rapid
death
vascular
xenograft
strategi
prevent
hyperacut
reject
includ
deplet
antig
antibodi
genet
engin
swine
express
human
complement
regulatori
protein
porcin
xenograft
decreas
complement
deposit
tissu
injuri
howev
complement
regulatori
protein
also
serv
cellular
receptor
human
pathogen
eg
measl
swine
natur
suscept
consequ
possibl
human
measl
viru
might
given
opportun
grow
transgen
porcin
cell
capac
infect
either
transgen
swine
transgen
xenograft
human
host
also
notabl
natur
antibodi
may
provid
immunolog
defens
human
infect
retrovirus
parasit
common
organ
carri
gal
epitop
thu
deplet
antig
antibodi
may
theoret
allow
transmiss
porcin
virus
carri
gal
epitop
porcin
xenograft
host
howev
role
antibodi
vivo
remain
unknown
recent
number
knockout
swine
born
disrupt
gene
lack
target
sugar
har
xenograft
anim
surviv
longer
unmodifi
graft
h
sach
person
commun
use
knockout
organ
avoid
need
deplet
natur
antibodi
recipi
theoret
sideeffect
note
earlier
note
absenc
gal
sugar
cell
membran
knockout
porcin
xenograft
envelop
porcin
virus
produc
xenograft
lack
epitop
protect
provid
natur
antibodi
lost
similarli
toler
induct
antigenspecif
immunolog
unrespons
varieti
immunosuppress
regimen
studi
prevent
chronic
cellular
reject
occur
day
week
pigtononhumanprim
transplant
infecti
consequ
manipul
remain
determin
eg
toler
host
also
becom
toler
latent
endogen
infect
carri
graft
tissu
facilit
viru
transmiss
mani
organ
xenotrop
human
propos
subset
pose
tabl
categori
potenti
pathogen
result
xenotransplant
tradit
zoonosi
well
character
clinic
syndrom
human
eg
gondii
specif
diagnost
assay
gener
avail
speciesspecif
organ
incap
caus
infect
outsid
xenograft
eg
porcin
cmv
test
avail
standard
assay
avail
human
potenti
pathogen
organ
broad
host
rang
may
spread
beyond
xenograft
eg
adenoviru
specif
diagnost
assay
avail
unknown
pathogen
organ
known
human
pathogen
clinic
syndrom
microbiolog
assay
avail
new
virul
characterist
within
host
ie
xenotrop
organ
viral
recombin
result
intent
genet
modif
donor
diseas
result
multipl
simultan
infect
eg
lymphosi
cattl
result
babesia
viral
coinfect
particular
threat
immunocompromis
human
host
tabl
howev
without
confirm
anim
model
human
predict
remain
mere
educ
guess
base
experi
immunocompromis
human
exampl
rel
benign
organ
may
increas
virul
passag
new
host
evolutionari
adapt
may
caus
diseas
nativ
speci
caus
diseas
xenograft
recipi
accordingli
list
gener
guid
breed
sourc
anim
xenotransplant
includ
organ
thought
like
caus
diseas
xenograft
recipi
base
known
abil
infect
human
toxoplasma
gondii
similar
organ
commonli
caus
infect
transplant
recipi
eg
pocin
cytomegaloviru
organ
high
predilect
recombin
eg
parvoviru
addit
may
organspecif
exclus
list
eg
mycoplasma
sp
influenza
viru
lung
donor
list
inexact
absenc
clinic
experi
serv
varieti
purpos
progress
xenotransplant
includ
organ
thought
pose
unaccept
risk
recipi
bred
donor
herd
prospect
design
pathogenfre
dpf
microbiolog
assay
organ
develop
clinic
use
studi
preclin
xenograft
model
may
clarifi
biolog
organ
prophylact
strategi
develop
organ
remov
donor
organ
exclus
list
vari
donor
speci
use
intend
xenograft
accordingli
microbiolog
standard
must
dynam
rigor
test
subject
revis
base
experiment
clinic
data
standard
test
must
also
reflect
evolut
test
strategi
eg
new
quantit
molecular
assay
adjust
differ
immunosuppress
regimen
epidemiolog
archiv
tissu
serum
sampl
donor
anim
recipi
mandat
fda
guidelin
futur
use
track
unsuspect
novel
pathogen
clinic
trial
xenotransplant
exogen
retrovirus
hiv
transmit
human
tissu
organ
cell
transplant
associ
activ
infect
two
perva
b
infect
human
pig
cell
vitro
third
subgroup
pervc
infect
porcin
cell
infecti
form
remain
perv
famili
isol
unlik
encod
infecti
viru
owe
disrupt
openread
frame
orf
pig
erv
mrna
express
pig
tissu
breed
swine
test
date
express
amplifi
stimul
swine
peripher
blood
lymphocyt
vitro
variat
tissu
term
size
amount
perv
mrna
transcript
consist
vivo
recombin
andor
process
porcin
endogen
retrovirusa
b
infect
sever
human
cell
line
primari
cell
cultur
swine
classifi
accord
whether
peripher
blood
mononuclear
cell
pbmc
either
transmit
perv
human
cell
vitro
anim
term
either
transmitt
nontransmitt
hightit
humantrop
perv
isol
transmit
anim
recombin
perva
pervc
sequenc
although
site
recombin
vari
viral
sequenc
deriv
recombin
perva
element
postvra
envelop
region
pervc
therefor
although
pervc
capabl
infect
human
cell
appear
essenti
compon
hightit
humantrop
perv
swine
may
import
assess
infecti
risk
associ
xenotransplant
sourc
recombin
vivo
unknown
analysi
germlin
dna
transmit
anim
identifi
presenc
recombin
virus
thu
swine
incomplet
genom
proviru
ie
porcin
endogen
retroviru
without
complet
env
gene
might
abl
gener
infecti
recombin
virus
presenc
infecti
pervc
evid
infect
demonstr
human
cell
vivo
diseas
result
famili
virus
describ
swine
human
date
porcin
endogen
retroviru
appear
suscept
current
avail
antivir
agent
data
suggest
primari
cell
line
primat
baboon
gorilla
macaqu
infect
perva
b
possibl
c
enhanc
valu
preclin
studi
primat
howev
studi
question
valu
model
infect
nonhuman
primat
tissu
often
abort
whether
human
equal
nonpermiss
remain
determin
activ
latent
herpesviru
infect
period
intensifi
immun
suppress
immun
dysfunct
immun
reactiv
graft
reject
import
problem
human
allotransplant
compar
virus
exist
swine
tend
speciesspecif
would
expect
caus
infect
tissu
deriv
usual
host
speci
viral
strain
import
place
cytomegaloviru
cmv
caus
invas
tissu
diseas
fever
neutropenia
immun
modul
contribut
risk
secondari
infect
graft
reject
lymphoma
extens
molecular
screen
identifi
three
famili
herpesvirus
swine
porcin
cmv
porcin
lymphotrop
replic
porcin
cytomegaloviru
pcmv
enhanc
intens
immun
suppress
pigtoprim
model
xenotransplant
porcin
cytomegaloviru
infect
caus
tissueinvas
infect
porcin
xenograft
baboon
host
contribut
endotheli
injuri
consumpt
coagulopathi
cc
anim
base
molecular
histolog
evalu
pcmv
appear
caus
invas
diseas
tissu
baboon
receiv
porcin
xenograft
possibl
exclud
pcmv
herd
swine
earli
wean
newborn
absenc
pcmv
improv
graft
surviv
reduc
coagulopathi
pigtobaboon
xenotransplant
recent
data
suggest
porcin
cmv
reduc
suscept
ganciclovir
foscarnet
cidofovir
compar
human
strain
two
novel
famili
gammaherpesviru
identifi
swine
amplif
short
dna
polymeras
sequenc
pig
porcin
lymphotrop
porcin
lymphotrop
associ
syndrom
lymphoid
prolifer
swine
undergo
experiment
allogen
hematopoiet
stemcel
transplant
syndrom
characterist
similar
posttransplant
lymphoprolif
diseas
ptld
base
sequenc
analysi
viru
genet
homolog
known
sequenc
lymphocryptoviru
ebv
rhadinovirus
role
viru
pathogenesi
ptld
investig
porcin
allogen
hematopoiet
stemcel
transplant
risk
ptld
swine
relat
overal
intens
immun
suppress
mhc
dispar
donor
host
degre
tcell
deplet
plhv
activ
preced
bcell
prolifer
role
unknown
unlik
pcmv
remov
sourc
anim
earli
wean
newborn
varieti
potenti
human
pathogen
describ
swine
includ
porcin
circoviru
type
porcin
reproduct
respiratori
syndrom
viru
porcin
encephalomyocard
viru
swine
influenza
virus
african
swine
fever
viru
hepat
elik
viru
pseudorabi
viru
parvoviru
polyomavirus
swine
none
yet
associ
human
diseas
exposur
human
product
deriv
pig
nonhuman
speci
demonstr
advers
effect
individu
gener
popul
cesarianderiv
porcin
fetal
tissu
intend
human
xenotransplant
carri
antibodi
leptospira
interrogan
aspergillu
fumigatu
bacteri
viral
fungal
parasit
evalu
transplant
cell
prepar
neg
infect
report
transplant
human
transplant
porcin
fetal
brain
cell
treatment
refractori
parkinson
diseas
intract
seizur
minim
immun
suppress
achiev
without
infecti
complic
date
although
limit
number
clinic
trial
perform
recent
human
epidem
viral
infect
trace
animalderiv
strain
adapt
human
host
heighten
concern
possibl
animaltohuman
diseas
transmiss
xenotransplant
includ
hantaviru
mice
sar
sever
acut
respiratori
syndrom
owe
new
coronaviru
possibl
associ
civet
bse
bovin
spongiform
encephalopathi
hiv
human
immunodefici
viru
thought
evolv
primat
virus
case
epidemiolog
defin
recognit
new
clinic
syndrom
develop
new
rapid
molecular
assay
caus
agent
discuss
exampl
sporad
case
zoonot
human
infect
swine
influenza
virus
detect
unit
state
europ
asia
new
zealand
sinc
direct
evid
exposur
swine
influenza
virus
circul
mani
anim
host
may
serv
reservoir
human
diseas
case
virus
adapt
human
infect
caus
human
diseas
result
number
individu
affect
small
compar
number
involv
pig
farm
pig
may
also
serv
host
adapt
avian
respiratori
virus
human
host
thu
human
porcin
avian
virus
may
undergo
genet
reassort
swine
produc
novel
strain
pandem
potenti
possibl
infect
lung
xenograft
might
exampl
provid
petri
dish
recombin
porcin
human
influenza
virus
particularli
immunocompromis
host
theoret
concern
address
via
breed
herd
sourc
anim
isol
human
respiratori
virus
anim
caretak
adventiti
bird
rodent
given
highli
sensit
molecular
assay
feasibl
assur
pig
use
sourc
anim
xenograft
particularli
lung
screen
influenza
virus
similarli
hepat
e
viru
hev
major
caus
viral
hepat
develop
world
recent
detect
swine
north
america
asia
spread
hev
human
pig
demonstr
virus
found
swine
close
relat
genet
caus
human
diseas
suggest
pig
may
serv
reservoir
infect
clearli
would
merit
special
screen
anim
use
sourc
porcin
hepat
graft
xenograft
recipi
risk
infect
reject
necessit
lifelong
monitor
addit
recipi
intim
contact
recipi
might
also
increas
risk
xenogen
infect
individu
receiv
organ
transplant
infect
graft
reject
malign
etiolog
organ
dysfunct
often
indistinguish
clinic
ground
xenograft
recipi
sign
may
manifest
common
communityacquir
infect
latent
human
infect
reactiv
recipi
monitor
scheme
propos
detect
known
pathogen
archiv
specimen
sourc
anim
patient
intim
contact
anim
handler
routin
basi
use
event
unexplain
infecti
episod
sampl
may
util
microbiolog
assay
develop
previous
unrecogn
pathogen
routin
sampl
might
studi
emerg
pigderiv
pathogen
perv
herpesvirus
even
absenc
clinic
evid
infect
one
excit
area
research
use
newer
molecular
techniqu
broadrang
hybrid
probe
pcr
primer
molecular
differenti
display
microarray
technolog
appli
xenotransplant
detect
pathogen
pose
risk
xenograft
recipi
contact
possibl
unexpect
clinic
symptom
result
xenogen
infect
necessit
prepar
respons
key
featur
scheme
might
dissimilar
approach
taken
allograft
recipi
routin
bacteri
fungal
viral
cultur
perform
cell
human
pig
origin
initi
antimicrobi
therapi
pcr
perv
herpesvirus
ie
pcmv
hcmv
ebv
plhv
use
sera
leukocyt
cocultiv
peripher
blood
leukocyt
human
donorcel
line
follow
empir
antimicrobi
therapi
hospit
admiss
isol
patient
natur
process
defin
special
precaut
eg
respiratori
secret
neutropenia
dictat
patient
clinic
present
event
recognit
novel
recombin
organ
sever
infecti
ill
without
explan
strict
isol
hepa
filtrat
requir
assess
infecti
risk
associ
clinic
xenotransplant
central
accept
technolog
optim
patient
care
thu
import
investig
potenti
pathogen
preclin
model
xenograft
recipi
signific
progress
made
defin
risk
result
known
pathogen
identif
perv
virus
allow
develop
sensit
assay
agent
strategi
exclus
pathogen
xenograft
donor
may
addit
human
pathogen
swine
yet
identifi
identifi
preclin
model
other
may
appear
clinic
trial
thu
essenti
investig
share
clinic
preclin
data
suggest
presenc
unusu
infecti
event
xenotransplant
without
commit
share
epidemiolog
data
occasion
infecti
event
novel
syndrom
like
remain
unrecogn
epidemiolog
radar
screen
approach
share
data
intern
address
see
consult
xenotransplant
surveil
sponsor
oecd
health
canada
http
wwwoecdorg
emphas
need
share
definit
xenogen
infecti
diseas
event
case
definit
laboratori
assay
specif
organ
intern
cooper
report
record
respons
advers
event
associ
xenotransplant
concern
regard
potenti
infecti
risk
xenotransplant
gener
overwhelm
discuss
potenti
benefit
technolog
howev
major
infecti
hazard
current
confront
human
allotransplant
address
via
elect
xenotransplant
becom
practic
broad
clinic
applic
uniqu
benefit
xenotransplant
deriv
r
care
microbiolog
screen
anim
use
xenotransplant
compar
limit
screen
human
tissu
perform
allotransplant
r
potenti
resist
xenogen
tissu
infect
human
pathogen
includ
hiv
htlv
hepat
virus
herp
virus
includ
human
cmv
exampl
porcin
cytomegaloviru
appear
infect
baboon
tissu
vivo
speci
specif
may
reflect
absenc
receptor
cellular
machineri
necessari
viral
replic
human
cell
r
limit
durat
exogen
immun
suppress
compon
mani
propos
xenotransplant
protocol
includ
immunolog
toler
induct
may
reduc
risk
opportunist
infect
r
patient
receiv
transplant
time
greatest
clinic
need
reduc
durat
pretranspl
hospit
exposur
nosocomi
pathogen
also
avoid
prolong
hospit
colon
common
mani
deceas
donor
signific
advanc
made
microbiolog
xenotransplant
concern
regard
xenotransplant
rais
author
other
clinic
trial
first
propos
focus
larg
pathogen
could
remov
select
breed
endogen
retrovirus
possibl
herp
virus
swine
data
gener
past
year
suggest
risk
human
infect
result
xenotransplant
manag
risk
spread
infect
contact
xenograft
recipi
appear
low
care
screen
earli
wean
donor
swine
exclud
mani
potenti
human
pathogen
isol
herd
routin
microbi
surveil
unfortun
risk
infect
never
zero
studi
swine
elucid
pathogen
mechan
eg
retrovir
recombin
pathogenesi
posttranspl
lymphoma
current
data
suggest
howev
consider
reason
given
research
barrier
clinic
xenotransplant
immun
metabol
prelud
clinic
trial
